A study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Study identifier:D2285M00032

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, placebo-controlled, three-way cross-over single center study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Medical condition

Morton's neuroma

Phase

N/A

Healthy volunteers

Study drug

Xylocaine, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 01 Feb 2011

Primary Completion Date: 01 May 2012

Study Completion Date: 01 May 2012

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Stockholm, Sweden

Arms	Assigned Interventions
Active Comparator: Xylocaine_1mg 1 injection of Xylocaine (1 mg/mL)	Drug: Xylocaine 1 mg/mL solution for injection
Active Comparator: Xylocaine_10mg 1 injection of Xylocaine (10 mg/mL)	Drug: Xylocaine 10 mg/mL solution for injection
Placebo Comparator: Placebo 1 injection of placebo	Drug: Placebo solution for injection

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1251&filename=CSR-D2285M00032.pdf
Download
CSR-D2285M00032.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Bror Jonzon

AstraZeneca R&D Södertälje, Sweden